NBIX - ニュ―ロクライン・バイオサイエンシズ (Neurocrine Biosciences Inc.) ニュ―ロクライン・バイオサイエンシズ

 NBIXのチャート


 NBIXの企業情報

symbol NBIx
会社名 Neurocrine Biosciences Inc. (ニュ―ロクライン・バイオサイエンシズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ニューロクライン・バイオサイエンシス(Neurocrine Biosciences Inc)は神経と内分泌関連疾患及び障害の治療薬の発見・開発・商業化に従事する企業。同社の薬品候補は子宮内膜症、ストレス関連疾患、疼痛、糖尿病、不眠症、及び他の神経と内分泌関連疾患及び障害などの製薬市場に提供する。同社は各自の研究・開発段階にある11のプログラムを持ち、そのうち、6つのプログラムは臨床開発段階にある。同社は6つのプログラムのためのコラボレーションを締結した。同社の主要な臨床開発プログラム「elagolix」は子宮内膜症治療用の薬剤候補。同社の製品ポートフォリオは「Elagolix」、小胞モノアミントランスポーター2阻害剤(VMAT2)、コルチコトロピン遊離因子タイプ2(CRF2)ペプチド・アゴニストウロコルチン、コルチコトロピン遊離因子タイプ1(CRF1)拮抗薬(561679)、コルチコトロピン遊離因子タイプ1(CRF1)拮抗薬(586529)、Gタンパク質共役型受容体119(GPR119)、VMAT2、性腺刺激ホルモン放出ホルモン(GnRH)拮抗薬、抗てんかん薬、Gタンパク質共役受容体と「Indiplon」などを含む。   ニュ―ロクライン・バイオサイエンシズは米国のバイオ医薬品メ―カ―。主に、神経及び内分泌関連疾患や障害である、子宮内膜症、糖尿病、睡眠障害、疼痛、ストレス性障害、てんかんなどの治療薬の臨床・開発に従事する。カリフォルニア州サンディエゴに拠点を置き、世界的に事業を展開。   Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, Neurocrine Biosciences has specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems.
本社所在地 12780 El Camino Real San Diego CA 92130 USA
代表者氏名 William H. Rastetter ウィリアムH.ラスターセッター
代表者役職名 Independent Chairman of the Board
電話番号 +1 858-617-7600
設立年月日 33604
市場名 NASDAQ National Market System
ipoyear 1996年
従業員数 400人
url www.neurocrine.com
nasdaq_url https://www.nasdaq.com/symbol/nbix
adr_tso
EBITDA EBITDA(百万ドル) -30.46900
終値(lastsale) 112.3
時価総額(marketcap) 10159709240.3
時価総額 時価総額(百万ドル) 9776.119
売上高 売上高(百万ドル) 323.28200
企業価値(EV) 企業価値(EV)(百万ドル) 9646.264
当期純利益 当期純利益(百万ドル) -51.96200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Neurocrine Biosciences Inc. revenues increased from $6.3M to $168M. Net loss decreased 65% to $47.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Investment income net increase from $1.9M to $6.3M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$1.58 to -$0.53.

 NBIXのテクニカル分析


 NBIXのニュース

   Neurocrine Biosciences to Present at Upcoming Healthcare Conferences  2021/09/02 20:13:00 Neurocrine Biosciences
SAN DIEGO , Sept. 2, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following virtual investor conferences: Kevin Gorman , Chief Executive Officer, will present at the Morgan Stanley 19 th Annual
   The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma  2021/08/12 12:09:26 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (NASDAQ: ADGI ) (IPOed Friday) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Cytek Biosciences, Inc. (NASDAQ: CTKB ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Eliem Therapeutics, Inc. (NASDAQ: ELYM ) (IPOed Monday) Erasca, Inc. (NASDAQ: ERAS ) (IPOed July 16) Fulcrum Therapeutics, Inc. (NASDAQ: FULC ) (reacted to positive analyst actions following a positive clinical readout) IN8bio, Inc. (NASDAQ: INAB ) Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD ) Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI ) (announced second-quarter results) Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE ) Rani Therapeutics Holdings, Inc. (NASDAQ: RANI ) (IPOed July 30) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 11) Adicet Bio, Inc. (NASDAQ: ACET ) Akero Therapeutics, Inc. (NASDAQ: AKRO ) Allogene Therapeutics, Inc. (NASDAQ: ALLO ) Aptose Biosciences Inc.
   Neurocrine Biosciences Trading Near Its 52-Week Low As Delta Threatens The Ingrezza Rebound  2021/08/11 14:00:00 Seeking Alpha
   Neurocrine Biosciences, Inc. 2021 Q2 - Results - Earnings Call Presentation  2021/08/04 08:41:34 Seeking Alpha
   Neurocrine Biosciences EPS misses by $0.13, beats on revenue  2021/08/03 20:04:09 Seeking Alpha
   Neurocrine Biosciences Q2 2021 Earnings Preview  2021/08/02 21:35:55 Seeking Alpha
   Immunotoxins Market 2021 SWOT Analysis, Competitive Landscape and Significant Growth | Top Brands:Biotest, Celldex Therapeutics, Amgen, Genmab, AREVA Med, Bayer HealthCare, Neurocrine Biosciences,   2021/07/25 14:19:10 Jumbo News
This report studies the Immunotoxins Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Immunotoxins market segmented by company, region, type and applications []
   United States Parkinson''s Disease Market Insights, Epidemiology and Outlook to 2030 | Addex Pharma, AbbVie, Prevail Therapeutics, Denali Therapeutics, Neurocrine Biosciences, and More  2021/07/23 20:45:00 Business Insider Markets
DUBLIN, July 23, 2021 /PRNewswire/ -- The
   Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2021 Financial Results  2021/07/19 20:01:00 PR Newswire
SAN DIEGO, July 19, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report second quarter 2021 financial results after the Nasdaq market closes on Tuesday, August 3, 2021. Neurocrine will then host a conference call and webcast to discuss its
   Essential Tremor Treatment Market Growth 2021-2026: Merz Pharma GmbH & Co KgaA , Neurocrine Biosciences Inc , Sage Therapeutics Inc  2021/07/09 13:45:02 Tramways Monthly
Essential Tremor Treatment Market analysis report is sure to help boost sales and improve return on investment (ROI). The research and analysis carried out in this Essential Tremor Treatment Market report assist clients to forecast investment in an emerging market, expansion of market share or success of a new product with the help of global […]
   Neurocrine Biosciences presents new muscarinic M4 receptor antagonists  2021/07/02 13:58:09 BioWorld
   Idorsia: Putting The Capstone On A Foundationally Strong Biotech  2021/06/10 17:51:23 Seeking Alpha
   Hematuria Treatment Market 2028 Analysis of Key Players Neurocrine Biosciences, Inc., Pfizer Inc., Biogen Inc., Teva Pharmaceutical Industries Ltd., AcelRx Pharmaceuticals  2021/06/01 16:17:28 OpenPR
A new market report by The Insight Partners on the Hematuria Treatment Market has been released with reliable information and accurate forecasts for a better understanding of the current and future market scenarios. The report offers an in-depth analysis of
   Neurocrine Biosciences to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference  2021/06/01 00:00:00 BioSpace
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Goldman Sachs 42nd Annual Global Healthcare Conference at 1:20 p.m. Eastern Time on Tuesday, June 8, 2021. Kevin Gorman, Chief Executive Officer, will present at the conference.
   Neurocrine Biosciences: Pandemic Pressures And Few Pipeline Catalysts Continue To Weigh On NBIX  2021/05/26 13:25:00 Seeking Alpha

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ニュ―ロクライン・バイオサイエンシズ NBIX Neurocrine Biosciences Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)